Medicare Part D spending · FDA facts · help paying
Tagrisso (osimertinib): what Medicare Part D spends and the dated federal facts we hold
CMS's Medicare Part D spending dataset reports gross spending on Tagrisso of $1.63 billion in 2024, across 96,403 claims and 12,370 beneficiaries. 2 non-manufacturing label changes are dated in the last 12 months in the FDA's file.
When could a generic arrive
Each date below is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
| Application | Product | Latest listed patent expiry | Latest listed exclusivity expiry | Latest of the two | Set by |
|---|---|---|---|---|---|
| NDA208065 | Tagrisso | November 26, 2042 | December 18, 2027 | November 26, 2042 | patent 12465608; 16 dated entries listed |
Source: FDA Orange Book data files, edition September 2026, read November 7, 2026; patent listings are as submitted by applicants and not verified by FDA. FDA data file.
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Tagrisso of $1.63 billion in 2024, across 96,403 claims and 12,370 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $1.63 billion | 96,403 | 12,370 | $16,878 |
| 2023 | $1.23 billion | 70,847 | 9,387 | $17,389 |
| 2022 | $1.08 billion | 64,678 | 8,629 | $16,718 |
| 2021 | $913.27 million | 56,038 | 7,780 | $16,297 |
| 2020 | $793.48 million | 49,761 | 7,016 | $15,946 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Rare-disease (orphan) designations
The FDA's orphan drug database lists 5 designations for osimertinib, 5 with an approval recorded. A designation is not an approval and not a statement that the drug treats the condition; the status column is the database's own.
| Designated | Designated use | Status | Sponsor |
|---|---|---|---|
| September 4, 2014 | Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer | Designated/Approved | AstraZeneca Pharmaceuticals LP |
| September 4, 2014 | Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer | Designated/Approved | AstraZeneca Pharmaceuticals LP |
| September 4, 2014 | Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer | Designated/Approved | AstraZeneca Pharmaceuticals LP |
| September 4, 2014 | Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer | Designated/Approved | AstraZeneca Pharmaceuticals LP |
| September 4, 2014 | Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer | Designated/Approved | AstraZeneca Pharmaceuticals LP |
Source: FDA Orphan Drug Designations and Approvals database, read November 7, 2026. FDA orphan drug search.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2024, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 10 states with the largest reimbursement are shown of 29 with data. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| CA | 2,372 | $43,282,922 | Fee-for-service only |
| NY | 1,794 | $31,867,281 | Fee-for-service only |
| IL | 411 | $6,465,423 | Fee-for-service only |
| WA | 349 | $5,687,841 | Fee-for-service only |
| FL | 318 | $5,439,546 | Fee-for-service only |
| PA | 306 | $5,015,368 | Fee-for-service only |
| MA | 217 | $3,745,809 | All record types |
| OH | 210 | $3,538,328 | Fee-for-service only |
| MI | 206 | $3,463,145 | All record types |
| NJ | 212 | $3,098,032 | Fee-for-service only |
Where the publisher suppresses small managed-care cells, a state's figure covers fee-for-service claims only and understates use (19 state and package figures are marked that way here). A state missing from the table means its figures were suppressed or not reported, not zero use.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2024, modified 2026-07-13T15:37:28Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Medicaid spending
CMS's Medicaid spending dataset reports $174.89 million for Tagrisso in 2024. CMS's dataset states spending includes Federal and State reimbursement and dispensing fees and is not reduced by Medicaid rebates paid to the states. Spending is what Medicaid paid, not what a patient pays.
| Year | Spending | Claims |
|---|---|---|
| 2024 | $174.89 million | 10,103 |
| 2023 | $164.17 million | 10,133 |
| 2022 | $138.17 million | 8,786 |
| 2021 | $118.27 million | 7,986 |
| 2020 | $104.47 million | 7,125 |
Source: CMS Medicaid spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. A national drug-level aggregate; it says nothing about any state's coverage rules.
Federal formulary status
VA national formulary
The VA's national formulary files list the ingredient osimertinib, which covers every maker's product with that ingredient, not only Tagrisso. Each row is a VA national drug file entry and its status.
| VA entry | Status | Active NDCs |
|---|---|---|
| OSIMERTINIB TAB | National Formulary | 4 |
Source: VA Pharmacy Benefits Management national formulary (va-formulary-2026-09), read November 7, 2026. VA formulary page.
Where help paying exists
No program in our finder currently lists this drug as open to new patients.
Label changes
FDA actions on the applications behind Tagrisso dated since November 11, 2025, leaving out manufacturing (CMC) changes. 2 changes in the window.
| Date | Class | Application | Submissions | FDA documents |
|---|---|---|---|---|
| September 14, 2026 | Labeling | NDA208065 | 36 | Label (PDF) posted September 22, 2026FDA letter posted September 15, 2026 |
| September 14, 2026 | Efficacy | NDA208065 | 35 | Label (PDF) posted September 22, 2026FDA letter posted September 15, 2026 |
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Questions
Does Medicare have a negotiated price for Tagrisso?
The CMS negotiated-price file we read does not list Tagrisso, so this page shows no negotiated price. A drug appears in that file only when CMS selects it for negotiation, and not being listed says nothing about what it costs a patient.
Is there help paying for Tagrisso?
No program in our finder lists this drug yet.
When could a generic version of Tagrisso arrive?
For Tagrisso, the FDA's Orange Book (edition September 2026) lists these latest patent or exclusivity expiry dates by application: NDA208065, November 26, 2042. Each date is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
How much does Medicare Part D spend on Tagrisso?
CMS's Medicare Part D spending dataset reports gross spending on Tagrisso of $1.63 billion in 2024, across 96,403 claims and 12,370 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns the generic-entry upper bound, label history, recalls, trials, assistance and Part D spending, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/tagrisso.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. This drug is not in the CMS negotiated-price file, so no price source is used. Program details read from each program's own pages; CMS Medicare Part D spending by drug; CMS Medicaid spending by drug; TRICARE and VA formulary files; FDA Drugs@FDA and Orange Book data files. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.